Endometriosis. Endometriosis
Conditions
Interventions
Intervention 1: Letrozole tablet (2.5mg/day),calcium (1000mg/day) and vitamin D (800 IU/day). Intervention 2: Danazole tablet (600mg/day), calcium (1000mg/day) and vitamin D (800 IU/day). Intervention
Treatment - Drugs
Placebo
Letrozole tablet (2.5mg/day),calcium (1000mg/day) and vitamin D (800 IU/day)
Danazole tablet (600mg/day), calcium (1000mg/day) and vitamin D (800 IU/day)
Placebo group received 2 calcium tablets/day (each tablet=500mg) and vitamin D (800 IU/day)
Sponsors
Medical University of Isfahan
Eligibility
Sex/Gender
Female
Age
18 Years to 44 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria were: women in reproductive age with regular menstruation cycles (18 to 45 days), confirmed endometriosis in laparoscopy, chronic pelvic pain and dysmenorrhoea for at least 2 weeks in each month during past 3 months. Exclusion criteria were: abnormal vaginal bleeding with unknown cause, ovarian cyst >2cm, hormone therapy during past 3 months, osteopenia, smoking, hypersensitivity to danazole and letrozole, history of convulsion, pulmonary, cardiac, hepatic or renal diseases, cerebrovascular disease and pregnancy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of endometriosis. Timepoint: Every month. Method of measurement: VAS. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dysmenorhea. Timepoint: every month. Method of measurement: VAS and pelvic examination.;Pelvic pain. Timepoint: every month. Method of measurement: VAS and pelvic examination.;Dysparonia. Timepoint: every month. Method of measurement: VAS and pelvic examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Hatave Ghasemi Tehrany
Medical Isfahan University
Outcome results
None listed